FDA Approves Nivolumab With Ipilimumab for Unresectable or Metastatic Hepatocellular Carcinoma

On April 11, the US Food and Drug Administration (FDA) approved nivolumab with ipilimumab for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma.

For more information, read the FDA announcement or the Bristol Myers Squibb press release.

Posted on 4/11/2025